title: HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Yazaki
authors.forename: Junko
authors.initials: J
authors.lastname: Tanuma
authors.forename: Miwako
authors.initials: M
authors.lastname: Honda
authors.forename: Ikumi
authors.initials: I
authors.lastname: Genka
authors.forename: Katsuji
authors.initials: K
authors.lastname: Teruya
authors.forename: Natsuo
authors.initials: N
authors.lastname: Tachikawa
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D015236:HLA-C Antigens / Q000235:genetics*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D015236:HLA-C Antigens; C524551:HLA-C*08 antigen; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine